Immunome Inc. IMNM
Immunome Inc. (Nasdaq: IMNM) is an oncology drug developer. Its lead program, varegacestat (AL102), is in Phase 3 for progressing desmoid tumors. Its next catalyst on record is varegacestat: FDA PDUFA target action date for NDA (April 28, 2027).
Upcoming catalysts
- April 28, 2027varegacestat — FDA PDUFA target action date for NDA
assigned a Prescription Drug User Fee Act, or PDUFA, target action date of April 28, 2027
Next further out: IM-1335 — IND submission (Q4 2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| varegacestat | desmoid tumors (Phase 3 RINGSIDE positive; NDA under review) | small molecule | Phase 3 |
| IM-1021 (ROR1 ADC) | B-cell lymphoma / solid tumors | antibody | Phase 1 |
| IM-1617 (solid tumor ADC) | advanced solid tumors (CRC, NSCLC, breast) | antibody | Phase 1 |
| IM-3050 (FAP radioligand) | FAP-expressing solid tumors | radiopharmaceutical | Phase 1 |
| IM-1340 (solid tumor ADC) | NETs, lung, prostate and other carcinomas | antibody | Pre-clinical |
| IM-1335 (solid tumor ADC) | solid tumors | antibody | Pre-clinical |
Recent results and decisions
- Oct 2, 2026n/a Immunome entered into Amendment No. 4 to License Agreement with Bristol-Myers Squibb, removing all milestone and royalty payment obligations and assigning patent rights for varegacestat (formerly AL102) and AL101 to Immunome.
The Amendment removes the Company's obligation to make any milestone and royalty payments under the License Agreement and assigns to the Company patent rights related to varegacestat (formerly AL102) and AL101 that were previously licensed to the Company under the License Agreement.
Filing - Oct 2, 2026n/a Immunome paid BMS $20.0 million cash and issued 4,425,487 shares of common stock as consideration for the Amendment No. 4 to License Agreement.
As consideration for the Amendment, the Company paid BMS $20.0 million in cash and issued 4,425,487 shares of the Company's common stock.
Filing - Aug 11, 2026accepted FDA accepted the varegacestat NDA in July 2026 with a PDUFA target action date of April 28, 2027.
In July 2026, the U.S. FDA accepted Immunome’s NDA for varegacestat for the treatment of adults with desmoid tumors and assigned a PDUFA target action date of April 28, 2027.
Filing
3 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Merck & Co., Inc. MRK
- Astrazeneca PLC AZN
- Bristol Myers Squibb Co BMY
- BeOne Medicines Ltd. ONC
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.